Tempest Therapeutics (TPST) Competitors

$1.81 -0.05 (-2.69%)

Closing price 04:00 PM Eastern

Extended Trading

$1.80 -0.02 (-0.83%)

As of 04:52 PM Eastern

TPST vs. VRCA, PEPG, QTTB, LONA, and CGTX

Should you buy Tempest Therapeutics stock or one of its competitors? MarketBeat compares Tempest Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tempest Therapeutics include Verrica Pharmaceuticals (VRCA), PepGen (PEPG), Q32 Bio (QTTB), Athira Pharma (LONA), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry.

How does Tempest Therapeutics compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

In the previous week, Tempest Therapeutics had 3 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 3 mentions for Tempest Therapeutics and 0 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.00 beat Tempest Therapeutics' score of -1.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Verrica Pharmaceuticals	Neutral
Tempest Therapeutics	Negative

Verrica Pharmaceuticals presently has a consensus target price of $17.00, indicating a potential upside of 188.14%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Verrica Pharmaceuticals is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Verrica Pharmaceuticals has higher revenue and earnings than Tempest Therapeutics. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.85	-$17.89M	-$1.03	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

Tempest Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Tempest Therapeutics' return on equity of -355.61% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
Tempest Therapeutics	N/A	-355.61%	-121.21%

Verrica Pharmaceuticals has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.75, meaning that its stock price is 275% less volatile than the broader market.

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 6.3% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Verrica Pharmaceuticals beats Tempest Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Tempest Therapeutics compare to PepGen?

PepGen (NASDAQ:PEPG) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

PepGen currently has a consensus price target of $11.60, suggesting a potential upside of 653.25%. Given PepGen's stronger consensus rating and higher probable upside, research analysts plainly believe PepGen is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, PepGen had 7 more articles in the media than Tempest Therapeutics. MarketBeat recorded 10 mentions for PepGen and 3 mentions for Tempest Therapeutics. PepGen's average media sentiment score of 0.87 beat Tempest Therapeutics' score of -1.00 indicating that PepGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PepGen	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tempest Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

58.0% of PepGen shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 1.3% of PepGen shares are held by company insiders. Comparatively, 6.3% of Tempest Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

PepGen has a beta of 2.01, indicating that its share price is 101% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.75, indicating that its share price is 275% less volatile than the broader market.

PepGen is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

PepGen's return on equity of -59.89% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Tempest Therapeutics	N/A	-355.61%	-121.21%

Summary

PepGen beats Tempest Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Tempest Therapeutics compare to Q32 Bio?

Tempest Therapeutics (NASDAQ:TPST) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 6.3% of Tempest Therapeutics shares are held by company insiders. Comparatively, 40.0% of Q32 Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Q32 Bio has higher revenue and earnings than Tempest Therapeutics. Tempest Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
Q32 Bio	$53.74M	1.74	$29.82M	$2.66	2.07

Q32 Bio has a consensus target price of $13.00, suggesting a potential upside of 136.36%. Given Q32 Bio's stronger consensus rating and higher probable upside, analysts clearly believe Q32 Bio is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Q32 Bio's return on equity of 149.23% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
Q32 Bio	N/A	149.23%	34.50%

Tempest Therapeutics has a beta of -1.75, indicating that its share price is 275% less volatile than the broader market. Comparatively, Q32 Bio has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market.

In the previous week, Tempest Therapeutics and Tempest Therapeutics both had 3 articles in the media. Q32 Bio's average media sentiment score of -0.73 beat Tempest Therapeutics' score of -1.00 indicating that Q32 Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tempest Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Q32 Bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Q32 Bio beats Tempest Therapeutics on 13 of the 13 factors compared between the two stocks.

How does Tempest Therapeutics compare to Athira Pharma?

Tempest Therapeutics (NASDAQ:TPST) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Tempest Therapeutics has a beta of -1.75, indicating that its stock price is 275% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market.

In the previous week, Tempest Therapeutics had 2 more articles in the media than Athira Pharma. MarketBeat recorded 3 mentions for Tempest Therapeutics and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.00 beat Tempest Therapeutics' score of -1.00 indicating that Athira Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tempest Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Athira Pharma has a consensus price target of $10.00, suggesting a potential downside of 0.70%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Athira Pharma is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Athira Pharma is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A

22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 6.3% of Tempest Therapeutics shares are held by insiders. Comparatively, 25.7% of Athira Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tempest Therapeutics' return on equity of -355.61% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
Athira Pharma	N/A	-381.01%	-225.74%

Summary

Athira Pharma beats Tempest Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Tempest Therapeutics compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

Cognition Therapeutics' return on equity of -72.68% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
Tempest Therapeutics	N/A	-355.61%	-121.21%

Cognition Therapeutics has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.75, meaning that its stock price is 275% less volatile than the broader market.

Cognition Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 3 articles in the media. Cognition Therapeutics' average media sentiment score of 0.40 beat Tempest Therapeutics' score of -1.00 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tempest Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 14.4% of Cognition Therapeutics shares are owned by company insiders. Comparatively, 6.3% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cognition Therapeutics presently has a consensus price target of $3.33, suggesting a potential upside of 166.67%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cognition Therapeutics is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Cognition Therapeutics beats Tempest Therapeutics on 11 of the 12 factors compared between the two stocks.

Get Tempest Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TPST vs. The Competition

Export

Metric	Tempest Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$26.81M	$3.02B	$6.34B	$12.29B
Dividend Yield	N/A	1.97%	2.80%	5.36%
P/E Ratio	-0.30	17.78	20.92	25.47
Price / Sales	N/A	253.28	521.15	73.36
Price / Cash	N/A	56.99	43.18	55.00
Price / Book	30.17	4.58	9.98	7.00
Net Income	-$26.26M	$74.99M	$3.55B	$335.16M
7 Day Performance	-13.40%	-2.38%	0.40%	-0.29%
1 Month Performance	2.26%	-4.15%	-0.02%	1.18%
1 Year Performance	-71.27%	36.30%	34.94%	34.78%

Tempest Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TPST Tempest Therapeutics	1.6621 of 5 stars	$1.81 -2.7%	N/A	-72.2%	$26.81M	N/A	N/A	20	Negative News Earnings Report Gap Down
VRCA Verrica Pharmaceuticals	1.4308 of 5 stars	$5.87 -6.4%	$17.00 +189.6%	-6.4%	$107.71M	$35.58M	N/A	40
PEPG PepGen	3.9999 of 5 stars	$1.47 -5.2%	$11.60 +689.1%	-8.9%	$107.21M	N/A	N/A	30	Analyst Forecast Gap Down
QTTB Q32 Bio	3.1681 of 5 stars	$5.75 -8.7%	$13.00 +126.1%	+220.3%	$106.82M	$53.74M	2.16	39	Analyst Downgrade
LONA Athira Pharma	1.2951 of 5 stars	$10.13 -10.0%	$10.00 -1.3%	N/A	$105.77M	N/A	N/A	40	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TPST) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tempest Therapeutics (TPST) Competitors

TPST vs. VRCA, PEPG, QTTB, LONA, and CGTX

How does Tempest Therapeutics compare to Verrica Pharmaceuticals?

Summary

How does Tempest Therapeutics compare to PepGen?

Summary

How does Tempest Therapeutics compare to Q32 Bio?

Summary

How does Tempest Therapeutics compare to Athira Pharma?

Summary

How does Tempest Therapeutics compare to Cognition Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST vs. The Competition

Tempest Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tempest Therapeutics (TPST) Competitors

TPST vs. VRCA, PEPG, QTTB, LONA, and CGTX

How does Tempest Therapeutics compare to Verrica Pharmaceuticals?

Does the media refer more to VRCA or TPST?

Do analysts prefer VRCA or TPST?

Which has stronger valuation & earnings, VRCA or TPST?

Is VRCA or TPST more profitable?

Which has more risk & volatility, VRCA or TPST?

Do insiders & institutionals believe in VRCA or TPST?

Summary

How does Tempest Therapeutics compare to PepGen?

Do analysts recommend PEPG or TPST?

Does the media refer more to PEPG or TPST?

Do insiders and institutionals believe in PEPG or TPST?

Which has more risk & volatility, PEPG or TPST?

Which has stronger earnings & valuation, PEPG or TPST?

Is PEPG or TPST more profitable?

Summary

How does Tempest Therapeutics compare to Q32 Bio?

Do insiders & institutionals hold more shares of TPST or QTTB?

Which has preferable earnings and valuation, TPST or QTTB?

Do analysts prefer TPST or QTTB?

Is TPST or QTTB more profitable?

Which has more risk & volatility, TPST or QTTB?

Does the media prefer TPST or QTTB?

Summary

How does Tempest Therapeutics compare to Athira Pharma?

Which has more volatility & risk, TPST or LONA?

Does the media prefer TPST or LONA?

Do analysts rate TPST or LONA?

Which has stronger valuation and earnings, TPST or LONA?

Do insiders and institutionals hold more shares of TPST or LONA?

Is TPST or LONA more profitable?

Summary

How does Tempest Therapeutics compare to Cognition Therapeutics?

Is CGTX or TPST more profitable?

Which has more volatility & risk, CGTX or TPST?

Which has preferable earnings & valuation, CGTX or TPST?

Does the media favor CGTX or TPST?

Do institutionals and insiders hold more shares of CGTX or TPST?

Do analysts recommend CGTX or TPST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST vs. The Competition

Tempest Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools